Prednisone/prednisolone and Deflazacort act predominantly by inhibiting NF-κB signaling, a function that has shown long-term protective effects and serves as the gold standard for the treatment of DMD [53,54] to mitigate damage to both skeletal and cardiac muscle. The gene discussed is NFKB1; the disease is Duchenne muscular dystrophy.